IN8BIO, INC.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
INAB$0.90-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(5,090) | $(5,550) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 245 | 256 |
| Non-cash stock-based compensation | 401 | 831 |
| Amortization of finance lease right-of-use assets | 108 | 240 |
| Amortization of operating lease right-of-use assets | 147 | 173 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 67 | 621 |
| Other non-current assets | 17 | — |
| Accounts payable | 140 | 186 |
| Accrued expenses and other current liabilities | (952) | 98 |
| Short-term operating lease liabilities | 206 | 164 |
| Long-term operating lease liabilities | (236) | (141) |
| Net cash used in operating activities | (4,947) | (3,122) |
| Investing activities | ||
| Purchases of property and equipment | (9) | — |
| Net cash used in investing activities | (9) | — |
| Financing activities | ||
| Payment of issuance costs from December 2025 issuance of common stock | (88) | — |
| Proceeds from the issuance of common stock, net of issuance costs | — | 3,735 |
| Proceeds from the exercise of Series C warrants, net of issuance costs | — | 383 |
| Principal payments on finance leases | (107) | (225) |
| Net cash (used in) provided by financing activities | (195) | 3,893 |
| Net (decrease) increase in cash and restricted cash | (5,151) | 771 |
| Cash and restricted cash at beginning of period | 27,312 | 11,386 |
| Cash and restricted cash at end of period | $22,161 | $12,157 |
| Cash, end of period | $21,941 | $11,888 |
| Restricted cash, end of period | 220 | 269 |
| Cash and restricted cash, end of period | $22,161 | $12,157 |
| Supplemental disclosure of non-cash financing and investing activities: | ||
| Lease modification of operating lease right-of-use assets and liabilities | $(291) | $(557) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.